Objective: To investigate the roles of different cells in the pulmonary lesions in the severe acute respiratory syndrome (SARS) patients.
Methods: The monoclonal antibodies of CD8, CD20, CD34, LCA, CD56, CD68, and AE1/AE3 are used to demonstrate the different cells in the lung specimens of SARS patients in order to study the patterns of cell responses in this new disease. Meanwhile the HE stained slides were also carefully studied to compare with the results of immunohistochemical staining.
Results: The number of capillaries increased and the capillaries clearly outlined the contour of alveolar wall from beginning to early stage of organization, the number of lymphocytes decreased sharply while the number of macrophage remarkably increased, together with proliferation of type II pneumocytes. The numbers of blood vessels decreased in the fibrotic and consolidated lung tissue, and the vessel cavities enlarged, losing the normal contour of alveolar septa.
Conclusions: The lesions in the lung from SARS patients are consisted of the tissue reaction to the inflammatory injury, including extensive exudation, capillary proliferation, fibrosis, and obvious infiltration of macrophages which may play a key role in the pathogenesis of pulmonary lesions of SARS.
Download full-text PDF |
Source |
---|
Alzheimers Dement
December 2024
RWJ Barnabas Health, West Orange, NJ, USA.
Background: Effect and Safety of Electroconvulsive Therapy plus Usual Care for the Acute Management of Severe Agitation in Dementia (ECT-AD) is a multi-site NIA-funded FDA-regulated pioneering clinical trial to investigate the effectiveness of electroconvulsive therapy (ECT) in treating severe and treatment-refractory agitation and aggression among individuals with advanced dementia, a condition that has a profound negative impact on patient quality of life and caregiver burden. Here we present baseline demographics of the patient population in this ongoing trial.
Method: To date we have enrolled 18 participants, with a mean age of 74.
Alzheimers Dement
December 2024
BioXcel Therapeutics, New Haven, CT, USA.
Background: BXCL501, a sublingual film formulation of dexmedetomidine, a highly selective α2 adrenoceptor agonist, is currently being studied for the acute treatment of agitation associated with dementia.
Method: This was a Phase 1b/2 study assessing efficacy and tolerability of BXCL501 for treatment of acute agitation associated with dementia. Subjects were randomized to active treatment with BXCL501 (30, 40, or 60µg) or placebo.
Alzheimers Dement
December 2024
Tulane University, New Orleans, LA, USA.
Background: Vascular dementia (VaD), the second most common cause of dementia, is characterized by cognitive decline due to reduced cerebral blood flow and blood-brain barrier disruption. Current evidence demonstrates that not only are VaD patients at higher risk of severe COVID-19 illness and mortality, but also that pre-existing cognitive dysfunction/dementia is associated with increased COVID-19 incidence. Conversely, SARS-CoV-2 infection alone worsens dementia-related mild cognitive impairment (MCI) and increases risk of cognitive decline, supported by similar fMRI findings demonstrating hypoperfusion.
View Article and Find Full Text PDFClin Nurs Res
January 2025
Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Serbia.
The hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a major regulator of adaptive response to hypoxia, common in patients with severe coronavirus disease 2019 (COVID-19). In addition, HIF-1 alpha regulates the expression of the most important proteins necessary for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of cells. The study included 129 hospitalized COVID-19 patients.
View Article and Find Full Text PDFBackground: Hospitalized older adults, especially those with Alzheimer's Disease and Related Dementias (PwD), are at high risk for delirium and distressing behaviors. Using physical restraints leads to functional decline and increased mortality. Our project aims to reduce restraint use by implementing a 4Ms approach for enhanced delirium management.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!